hide-icon
Pattern illustration of a DNA helix with a blue background for the OGT corporate brand. (1)
CTA Icon

Do you have a colleague who would like to receive OGT's DNA Dispatch newsletter?

Share this link

Welcome to the latest edition of DNA Dispatch, the quarterly newsletter from OGT, your hybridization experts.

In case you missed it: Latest data for MRD detection in AML

First presented at the Association for Molecular Pathology (AMP) 2025 conference, this presentation from Sean Glenn, PhD — Director of Advanced Molecular Diagnostics Laboratory, Roswell Park Comprehensive Cancer Center — shares insights from a retrospective cohort study of research specimens collected from patients undergoing AML treatment.

The presentation encompasses:

  • An analysis of the clinical significance of MRD monitoring
  • A comparison of NGS-based MRD detection with traditional technologies
  • An evaluation of genomic profiling in retrospective research
In case you missed it: Latest data for MRD detection in AML Image

Celebrating laboratory professionals across the US Image

Celebrating laboratory professionals across the US

Recently OGT had an exciting week celebrating Medical Laboratory Professionals Week with labs all across the US! OGT experts visited partners across the region celebrating our amazing lab customers who are the backbone of technical innovation and analytical excellence.

A huge thank you to all the incredible professionals working behind the scenes of US healthcare. From supporting life-saving research to providing critical data, you drive healthcare forward every day.

New article

What is Design of Experiments (DOE) and how it can impact NGS workflows?

In our latest article learn how Design of Experiments (DOE) unlocks more reliable NGS workflows to help raise QC pass rates, reduce variation and lower cost per sample.

What is Design of Experiments (DOE) and how it can impact NGS workflows? Image

Targeting what matters in genomes worldwide with SureSeq NGS Panels Image

Targeting what matters in genomes worldwide with SureSeq NGS Panels

In a recent study* by from Hamilton Health Sciences and London Health Sciences Centre a SureSeq™ Myeloid Sequencing Panel was used as part of the NGS workflow to identify somatic mutations (JAK2, CALR or MPL) in triple‑negative MPN patients with extreme thrombocytosis, supporting the study’s molecular characterization of this rare patient subgroup.

Helping you get FISH right at the probe application step

We have brought together expert insight from all our FISH specialists for the probe application stage of the FISH protocol, including a step‑by‑step protocol video, practical tips and tricks and answers to frequently asked questions.

Helping you get FISH right at the probe application step Image

NGS data spotlight Image

From a study by Kingston Health Sciences Centre utilizing a SureSeq myPanel™

NGS data spotlight

The study showed how OGT’s probe design optimization significantly boosted target performance, during the development of a custom NGS panel for combined myeloid and lymphoid neoplasm analysis.

Don’t forget…Our FAS team can be contacted online with free support advice

 

* Providing links to these publications is intended for educational purposes only and does not replace independent professional judgement. OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented in these publications.